CME: Eyes Toward the Future in AMD: What’s New on the Horizon?

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Eyes Toward the Future in AMD: What’s New on the Horizon?

Eyes Toward the Future in AMD: What’s New on the Horizon?
Anti-VEGF drugs have revolutionized the treatment of nAMD, and now, clinical evidence is offering guidance on how we can further optimize outcomes.

Available credits: 0.50

Time to complete: 30 Minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Despite the progress made in the treatment of neovascular age-related macular degeneration, or nAMD, significant gaps still exist in its diagnosis and treatment. Fortunately, there are ways healthcare professionals can overcome these barriers using proven diagnostic strategies and the latest clinical evidence to raise the potential for more individualized treatment and to optimize outcomes.

  • Learning Objectives

    • Identify symptoms and patterns of nAMD to facilitate early detection and timely diagnosis;
    • Assess recently available and emerging key studies and clinical evidence to optimize anti-VEGF treatment outcomes;
    • Recognize and understand the clinician’s key role in overcoming the barriers (underdiagnosis, delays in anti-VEGF treatment initiation, lack of awareness, etc) associated with nAMD.
  • Disclosure of Conflicts of Interest

    According to the disclosure policy of the University of Cincinnati College of Medicine, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity.  All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati College of Medicine to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

    The following faculty has reported real or apparent conflicts of interest that have been resolved:

    Peter Kaiser, MD, PhD has disclosed the following relevant financial relationships:

    Aerie, Aerpio, Alcon, Allegro, Allergan, Bayer, Bausch and Lomb, BioEq GmbH, Biogen Idec, Boehringer Ingelheim, Carl Zeiss Meditec, Clearside Biomedical, Eyevensys, Galecto Biotech, Galimedix, Hospira, iRenix, jCite, Kala Pharmaceuticals, Kanghong, Kodiak, NGM Biopharmaceuticals, Novartis, Omeros, Opthea, Oxurioin (Thrombogenics), Regeneron, RegenexBio, Retinal Sciences, Roivant, Santen, SciFluor, Shire, Spark, Stealth Biotherapeutics, Verena (Digisight)

    John J. Russell, MD (host) has nothing to disclose.

    The following reviewers/planners/authors have reported real or apparent conflicts of interest:

    • Susan Tyler, MEd, CMP, CHCP, CME Director, has nothing to disclose
    • Bruce Gebhardt, MD, Professor Emeritus, CME Reviewer, has nothing to disclose.
    • Heather Muskopf, BS, Program Manager, has nothing to disclose.
    • Otto Ratz, MD, has nothing to disclose.
    • Christina Culbert, MSc, has nothing to disclose.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Commercial Support

    This CME activity is supported by an educational grant from Genentech and Regeneron Pharmaceuticals.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati College of Medicine nor CORE Medical Education, LLC, recommends the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati College of Medicine or CORE Medical Education, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Instructions for Participation

    There are no fees for participating in and receiving CME credit for this online activity. During the period of 5/31/2019 to 5/31/2020, participants must 1) read the CME information, including the learning objectives and faculty disclosures; 2) listen to the full content of the activity and reflect upon its teachings; 3) successfully complete the post-test with a passing score of 70% and the evaluation at the end of the activity.

    Participants who successfully complete the activity, post test and evaluation will have a statement of credit made available immediately.

  • System Requirements

    Hardware/Software requirements include
    • Windows XP, 2000, Vista, Windows 7 - Internet Explorer 6.0+
    • Macintosh 9.2, OS X 10.1+ Safari 4+
    • Additional Requirements: Macromedia Flash Player 10; Internal/external speakers; Broadband connection (DSL/cable) recommended

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio


Programs 12/14/19